Sophie Bakri, MD
Ophthalmology · Rochester, MNNPI 1861464455
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $165,002 of the $183,277 with a category attached, or 90.0%. It is spread thinly across 17 manufacturers, the largest accounting for just 20.1%. Reporting peaked in 2019 at $52,791 and has fallen 78.6% since, to $11,279 in 2025. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $1246.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- F. Hoffmann-la Roche AG$22K
- Eyepoint US, Inc.$21K
- Apellis Pharmaceuticals, Inc.$21K
- Novartis$20K
- Genentech, Inc.$18K
- plus $45K from 11 others
Across 23 payments — averaging $1818.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$42K
What the payments were for
- Consulting fees$165,00290%
- Speaking & faculty fees$10,2606%
- Travel & lodging$4,2942%
- Food & beverage$3,4012%
- Education$580%
- Gifts$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $36,778 |
| F. Hoffmann-la Roche AG | 14 | $21,508 |
| Eyepoint US, Inc. | 17 | $21,002 |
| Apellis Pharmaceuticals, Inc. | 9 | $20,849 |
| Novartis | 13 | $19,933 |
| Genentech, Inc. | 11 | $18,145 |
| Regeneron | 11 | $10,992 |
| Ocular Therapeutix, Inc. | 4 | $8,498 |
| Alimera Sciences, Inc. | 2 | $6,700 |
| Kala Pharmaceuticals, Inc. | 7 | $4,916 |
| Amgen | 2 | $3,932 |
| Thrombogenics, Inc. | 1 | $3,000 |
| Regeneron Healthcare Solutions, Inc. | 5 | $2,834 |
| Roche Products Limited | 1 | $2,355 |
| Carl Zeiss Meditec, Inc. | 2 | $1,695 |
| Bausch & Lomb Americas Inc. | 1 | $96 |
| AstraZeneca | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$183,277 in reported general payments places this provider in the 95th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Rochester
- John ChenRochester$82K
- Raymond IezziRochester$44K
- Arthur SitRochester$33K
- Muhammad BhattiRochester$24K
- Brittni ScruggsRochester$21K
- Sanjay PatelRochester$20K
- Matthew StarrRochester$16K
- Lilly WagnerRochester$15K
- John WoogRochester$6K
- James GarrityRochester$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.